Avidity Biosciences, Inc. (Nasdaq: RNA), has announced new positive AOC 1001 data demonstrating improvement in multiple functional endpoints and favorable long-term safety and tolerability in people living with myotonic dystrophy… Read More »
Avidity Announces New Positive AOC 1001 Data
Fall vaccine guide
Via Ranae Beeker, RN, here’s a clear and concise guide to recommended vaccines for the fall of 2023. For people with neuromuscular conditions, this is especially important because: Falling severely… Read More »
An ounce of prevention…
September is Fall Prevention Awareness Month and was the subject of our Wellness Hour. Falls are the second most common cause of injury leading to death. For a person with… Read More »
The FSHD Society Celebrates Fulcrum’s Milestone in the Fight Against FSHD
Fulcrum Therapeutics has announced successful completion of patient enrollment in REACH Phase 3 trial The FSHD Society is thrilled to announce a significant milestone in the battle against FSHD. Fulcrum… Read More »
FSHD Lab Day was empowering for all
Uniting the FSHD Community in Advancing Research by Nizar Saad, PhD, Columbus, Ohio On July 8th, our lab at Nationwide Children’s Hospital (NCH) in Columbus, Ohio, in collaboration with NCH,… Read More »